title: MINE (chemotherapy)
text: # MINE (chemotherapy)
  
  MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
  
  Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.
  
  The [R]-MINE regimen consists of:
  
  * Rituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
  * Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
  * Ifosfamide - an alkylating antineoplastic agent from oxazafosforine group;
  * Mitoxantrone - a synthetic anthracycline analogue (anthraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
  * Etoposide - a topoisomerase inhibitor.
  
  ## Dosing regimen
  
  | Drug | Dose | Mode | Days |
  | - | - | - | - |
  | Rituximab | 375 $mg/m^2$ | IV infusion | Day 1 |
  | Mesna | 1330 $mg/m^2$ | IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide | Days 1-3 |
  | Ifosfamide | 1330 $mg/m^2$ | IV infusion over 1h | Days 1-3 |
  | Mitoxantrone | 8 $mg/m^2$ | IV infusion | Day 1 |
  | Etoposide | 65 $mg/m^2$ | IV infusion over 1h | Days 1-3 |
  